LUNG CANCER

Datopotamab deruxtecan for the treatment of advanced non–small cell lung cancer is ongoing investigation in multiple clinical trials.

In patients with metastatic non–small cell lung cancer given sacituzumab govitecan-hziy with pembrolizumab, positive response rates were observed.

According to Shirish M. Gadgeel, MD, adagrasib demonstrated durable clinical benefit [and] there were no new safety signals.

Se-Hoon Lee, MD, an oncologist at the Samsung Medical Center in Seoul, Korea, discusses his focus of research in the lung cancer space, including the phase 1 CHRYSALIS study of amivantamab and lazertinib in patients with EGFR-mutated non–small cell lung cancer.

As determined by phase 1 of the ARROS-1 study, patients with ROS1-positive non–small cell lung cancer and other solid tumors will be further assessed with the recommended phase 2 dose of NVL-520 in phase 2 of the trial.

Alectinib is the first and only ALK inhibitor to demonstrate a reduction in disease recurrence among patients with early-stage ALK-positive non–small cell lung cancer, based on data from the phase 3 ALINA study.

During a Targeted Oncology™ Community Case Forum™ event in partnership with The Arizona Clinical Oncology Society, Sujith R. Kalmadi, MD, reviewed data from the most important recent phase 3 trials of chemoimmunotherapy in advanced non–small cell lung cancer.

A retrospective study found no additional benefit for patients with non–small cell lung cancer who continued immunotherapy beyond 2 years.

During a Targeted Oncology™ Case-Based Roundtable™ event, Sandip P. Patel, MD, discussed the importance of patient characteristics and biomarkers in choosing an immunotherapy-containing regimen for patients with non–small cell lung cancer, particularly if their PD-L1 expression is low. This is the first of 2 articles based on this event.

Frontline treatment with AK112, a first-in-class humanized IgG1 bispecific antibody, plus chemotherapy demonstrated promising overall responses across 3 cohorts in a phase 2 trial.

During a Targeted Oncology™ Case-Based Roundtable™ event, Garrett B. Sherwood, MD, discussed biopsy and treatment approaches for a patient diagnosed with T2aN2M0, stage IIIA adenocarcinoma.

In an interview with Targeted Oncology, Se-Hoon Lee, MD, highlights the results of the long-term analysis of the CHRYSALIS trial looking at amivantamab and lazertinib for patients with EGFR mutated non–small cell lung cancer.

Dr. Florez and Dr. Sabari delve into areas of progress, unmet needs, and future research in NSCLC, encompassing novel biomarkers and targeted therapies such as CEACAM5.

Findings from a study published in JAMA Oncology showed no survival difference in fixed duration immune checkpoint inhibitor group vs the indefinite-duration group among patients with non–small cell lung cancer

Approval of pralsetinib for the treatment of RET fusion-positive non–small cell lung cancer in based on positive results from the phase 1/2 ARROW trial.

A positive association with progression-free survival in patients with advanced non–small cell lung cancer who were treated with first-line pembrolizumab was observed using a multiomics approach.

Important findings from the CARMEN-LC05 study evaluating tusa in combination with pembrolizumab and chemotherapy in NSCLC are discussed, highlighting their implications for clinical practice.

An overview of the CARMEN-LC03 and CARMEN-LC04 trials investigating tusa in different treatment settings for NSCLC and their impact on treatment approaches is provided.

Patients with RET fusion-positive advanced or metastatic non–small cell lung cancer had a survival benefit when treated with selpercatinib in the LIBRETTO-431 study.

In an interview with Targeted Oncology™, Patricia Rich, MD, discussed the data presented at ASCO 2023 and other recent trials that she found most exciting and important to the field of NSCLC treatment.

The transformative potential of antibody drug conjugates in NSCLC treatment is discussed, encompassing their design, bystander effect, biomarkers, and impact on the treatment landscape.

Dr. Florez and Dr. Sabari discuss standards of care for different patient populations in NSCLC.

Jonathan W. Goldman, MD, discusses the use of osimertinib in the first line setting for patients with non–small cell lung cancer.

Hatim Husain, MD, discussed with participants the case of a patient with lung adenocarcinoma.

In the second part of a 2-part article series, Kartik Konduri, MD, discusses the outcomes of targeting the KRAS G12C mutation in patients with metastatic NSCLC.

During a Targeted Oncology™ Case-Based Roundtable™ event, Garrett B. Sherwood, MD, discussed with participants what therapy to use, including adjuvant immunotherapy, for a patient with stage III non–small cell lung cancer. This is the second of 2 articles based on this event.

During a Targeted Oncology™ Clinical Case Forum™ event, Ronan J. Kelly, MD, MBA, discussed the significance of the CheckMate 9LA, KEYNOTE-407, EMPOWER-Lung 3, and POSEIDON studies which all explored immunotherapies in patients with advanced non–small cell lung cancer.

Without requiring additional therapy, 2 patients with non–small cell lung cancer treated with THIO and cemiplimab remained free of disease progression in the phase 2 THIO-101 study.

Rohit Gosain, MD, and Rahul Gosain, MD, provide a summary of the key NSCLC data updates discussed following the 2023 ASCO Annual Meeting.

A review of recently updated data from KEYNOTE-671, focused on perioperative use of pembrolizumab in early-stage non–small cell lung cancer.